SABS · SAB Biotherapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Sullivan Eddie Joe Chief Executive Officer | ▲ Buy | Open Market | 5,232,304 Shares held | 12/7/2023 | View profile |
| Hamilton Edward D. 10% Owner | ▲ Buy | Grant | 5,049,351 Shares held | 10/22/2021 | View profile |
| Christine E. Hamilton Director | ▲ Buy | Grant | 3,111,334 Shares held | 12/7/2022 | View profile |
| Ellias Helen K. | ▲ Buy | Option Exercise | 2,857,142 Shares held | 11/24/2023 | View profile |
| Andrew Moin | ▲ Buy | Option Exercise | 2,198,457 Shares held | 9/29/2025 | View profile |
| Sessa Capital (Master), L.P. Director | ▲ Buy | Option Exercise | 2,198,457 Shares held | 9/29/2025 | View profile |
| Spragens Jeffrey G Director | ▲ Buy | Grant | 394,989 Shares held | 12/7/2022 | View profile |
| Reich Samuel J CEO and CFO | ▲ Buy | Open Market | 219,001 Shares held | 11/29/2023 | View profile |
| Link David Charles Director | ▲ Buy | Grant | 57,313 Shares held | 12/7/2022 | View profile |
| Alexandra Kropotova CHIEF MEDICAL OFFICER | ▼ Sell | Tax Withholding | 41,853 Shares held | 9/17/2026 | View profile |
| Finnegan Frederick Chief Business Officer | ▲ Buy | Grant | 38,596 Shares held | 10/22/2021 | View profile |
| Luke Thomas Charles Chief Medical Officer | ▲ Buy | Grant | 5,428 Shares held | 10/22/2021 | View profile |
| King Michael CHIEF FINANCIAL OFFICER | ▲ Buy | Open Market | 5,000 Shares held | 11/30/2023 | View profile |
| Katz Ilan Director | ▲ Buy | Open Market | 1,500 Shares held | 10/13/2021 | View profile |
| Beyer Russell P Chief Financial Officer | ▼ Sell | Open Market | 0 Shares held | 10/26/2021 | View profile |
Transaction History
| Alexandra Kropotova | ▼ Sell | Tax Withholding | 473 | — | 9/17/2026 |
| Alexandra Kropotova | ▼ Sell | Tax Withholding | 988 | — | 6/25/2026 |
| Alexandra Kropotova | ▼ Sell | Tax Withholding | 988 | — | 3/24/2026 |
| Alexandra Kropotova | ▼ Sell | Tax Withholding | 988 | — | 12/11/2025 |
| Andrew Moin | ▲ Buy | Option Exercise | 1,740,000 | $3.0M | 9/29/2025 |
| Sessa Capital (Master), L.P. | ▲ Buy | Option Exercise | 1,740,000 | $3.0M | 9/29/2025 |
| Alexandra Kropotova | ▼ Sell | Tax Withholding | 1,977 | — | 9/19/2025 |
| Alexandra Kropotova | ▼ Sell | Tax Withholding | 1,179 | — | 3/27/2025 |
| Alexandra Kropotova | ▼ Sell | Tax Withholding | 9,072 | — | 12/18/2024 |
| Sullivan Eddie Joe | ▲ Buy | Open Market | 1,740 | $2K | 12/7/2023 |
| King Michael | ▲ Buy | Open Market | 5,000 | $5K | 11/30/2023 |
| Reich Samuel J | ▲ Buy | Open Market | 11,000 | $10K | 11/29/2023 |
| Sessa Capital (Master), L.P. | ▲ Buy | Option Exercise | 4,584,571 | — | 11/24/2023 |
| Andrew Moin | ▲ Buy | Option Exercise | 4,584,571 | — | 11/24/2023 |
| Ellias Helen K. | ▲ Buy | Option Exercise | 2,857,142 | — | 11/24/2023 |
| Alexandra Kropotova | ▲ Buy | Grant | 275,000 | — | 3/14/2023 |
| Christine E. Hamilton | ▲ Buy | Grant | 82,987 | $100K | 12/7/2022 |
| Spragens Jeffrey G | ▲ Buy | Grant | 82,987 | $100K | 12/7/2022 |
| Link David Charles | ▲ Buy | Grant | 41,493 | $50K | 12/7/2022 |
| Christine E. Hamilton | ▲ Buy | Open Market | 10,000 | $7K | 9/13/2022 |
| Sullivan Eddie Joe | ▲ Buy | Open Market | 14,000 | $10K | 9/7/2022 |
| Alexandra Kropotova | ▲ Buy | Grant | 300,000 | $0 | 6/6/2022 |
| Spragens Jeffrey G | ▼ Sell | Other | 299,002 | $0 | 5/20/2022 |
| Reich Samuel J | ▼ Sell | Other | 207,001 | $0 | 5/20/2022 |
| Reich Samuel J | ▼ Sell | Other | 2,500,127 | $0 | 5/20/2022 |
| Beyer Russell P | ▼ Sell | Open Market | 278 | $2K | 10/26/2021 |
| Beyer Russell P | ▲ Buy | Grant | 129 | $1K | 10/25/2021 |
| Link David Charles | ▲ Buy | Grant | 12,097 | — | 10/22/2021 |
| Sullivan Eddie Joe | ▲ Buy | Grant | 5,213,764 | — | 10/22/2021 |
| Christine E. Hamilton | ▲ Buy | Grant | 4,974,497 | — | 10/22/2021 |
| Link David Charles | ▲ Buy | Grant | 15,820 | — | 10/22/2021 |
| Hamilton Edward D. | ▲ Buy | Grant | 5,049,351 | — | 10/22/2021 |
| Christine E. Hamilton | ▲ Buy | Grant | 5,049,351 | — | 10/22/2021 |
| Luke Thomas Charles | ▲ Buy | Grant | 5,428 | — | 10/22/2021 |
| Hamilton Edward D. | ▲ Buy | Grant | 4,974,497 | — | 10/22/2021 |
| Finnegan Frederick | ▲ Buy | Grant | 38,596 | — | 10/22/2021 |
| Luke Thomas Charles | ▲ Buy | Grant | 990 | $10K | 10/19/2021 |
| Beyer Russell P | ▲ Buy | Grant | 2,475 | $25K | 10/18/2021 |
| Hamilton Edward D. | ▲ Buy | Grant | 5,092 | $51K | 10/14/2021 |
| Christine E. Hamilton | ▲ Buy | Grant | 5,092 | $51K | 10/14/2021 |
| Reich Samuel J | ▲ Buy | Open Market | 1,000 | $10K | 10/14/2021 |
| Hamilton Edward D. | ▲ Buy | Grant | 20,800 | $210K | 10/13/2021 |
| Katz Ilan | ▲ Buy | Open Market | 500 | $5K | 10/13/2021 |
| Christine E. Hamilton | ▲ Buy | Grant | 20,800 | $210K | 10/13/2021 |
| Christine E. Hamilton | ▲ Buy | Grant | 25,000 | $252K | 10/12/2021 |
| Hamilton Edward D. | ▲ Buy | Grant | 25,000 | $252K | 10/12/2021 |
| Hamilton Edward D. | ▲ Buy | Grant | 25,000 | $252K | 10/12/2021 |
| Christine E. Hamilton | ▲ Buy | Grant | 25,000 | $252K | 10/12/2021 |
| Sullivan Eddie Joe | ▲ Buy | Grant | 2,800 | $28K | 10/7/2021 |
| Hamilton Edward D. | ▲ Buy | Grant | 2,695 | $27K | 10/1/2021 |
| Christine E. Hamilton | ▲ Buy | Grant | 2,695 | $27K | 10/1/2021 |
| Spragens Jeffrey G | ▲ Buy | Open Market | 13,000 | $131K | 10/1/2021 |
| Katz Ilan | ▲ Buy | Open Market | 1,000 | $10K | 10/1/2021 |
| Beyer Russell P | ▲ Buy | Grant | 10 | $101 | 9/29/2021 |
| Beyer Russell P | ▲ Buy | Grant | 5 | $50 | 9/28/2021 |
| Beyer Russell P | ▲ Buy | Grant | 149 | $2K | 9/28/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting
SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting. SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.